Categories
Change Password!
Reset Password!
The updated non-mRNA COVID-19 vaccine offers targeted protection against Omicron variants for individuals 12+ with enhanced safety and efficacy.
According to a press release by the U.S. FDA on 30 August 2024, the newly updated non-mRNA COVID-19 vaccine designed to better protect against severe outcomes such as hospitalization and death has been granted emergency use authorization (EUA). This updated version is specifically tailored to target the Omicron variant JN.1, tackling currently circulating strains. Approved for individuals aged 12 and older, the vaccine offers a monovalent formulation and a vital option for COVID-19 prevention.
Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, highlighted the vaccine's role in ongoing COVID-19 prevention efforts, saying, "COVID-19 remains a significant risk, and today's authorization introduces another vaccine option that meets our laborious standards for safety and effectiveness."
Important Eligibility Updates:
The FDA’s approval follows an extensive assessment of manufacturing and clinical data, confirming the vaccine's safety profile. Side effects are expected to mirror those seen in previous vaccine versions, and the now-authorized formulation will replace the older 2023-2024 adjuvanted formula, which is no longer authorized for use.
FDA News Release
FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants
Comments (0)